Oct 20, 2021

Featuring perspectives from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics:

• Introduction (0:00)
• Prologue: A Personal Reflection on Acute Myeloid Leukemia (AML) (1:01)
• Case: A woman in her mid-80s with newly diagnosed AML — Daniel A Pollyea, MD, MS (8:28)
• Up-Front Treatment of AML in Patients Who Are Not Eligible for Intensive Therapy (11:54)
• Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (24:32)
• Management of AML with Targetable Mutations (33:14)
• Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (40:04)
• Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (48:41)
• Other Currently Available and Investigational Treatment Strategies for AML (51:57)
• Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (54:50)
• Case: A woman in her late 50s with leukemia cutis — Dr Wang (1:06:25)
• Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (1:09:20)
• Case: A man in his late 70s with high-risk MDS — Dr Sallman (1:15:37)
• Case: A man in his mid-80s with high-risk MDS — Dr Sallman (1:22:27)

CME information and select publications